What are the anesthetic considerations and concerns for a patient with limb‑girdle muscular dystrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Anesthetic Concerns for Limb Girdle Muscular Dystrophy

Patients with limb-girdle muscular dystrophy (LGMD) require trigger-free anesthesia using total intravenous anesthesia (TIVA) with absolute avoidance of volatile anesthetics and succinylcholine due to risks of rhabdomyolysis, hyperkalemia, and cardiac arrest. 1

Critical Pharmacologic Contraindications

Absolutely Contraindicated Agents

  • Succinylcholine: Causes acute rhabdomyolysis, hyperkalemia, and cardiac arrest through disruption of unstable cell membranes 2
  • Volatile anesthetics (halothane, isoflurane, sevoflurane): Trigger extreme hyperthermic events and rhabdomyolysis mimicking malignant hyperthermia 2

Safe Anesthetic Technique

Use TIVA with propofol and short-acting opioids (fentanyl, remifentanil) for induction and maintenance 2, 3. This approach has been successfully demonstrated in recent case reports of LGMD patients undergoing various surgical procedures 3, 4, 5.

Preoperative Evaluation Requirements

Cardiac Assessment

Cardiac involvement is very common in sarcoglycan-deficient LGMD (types 2C, 2D, 2E, 2F) and includes:

  • Dilated or hypertrophic cardiomyopathy
  • Atrial and ventricular arrhythmias
  • Heart block 1

Obtain cardiology consultation with echocardiogram to assess left ventricular function, as cardiac dysfunction may be present without clinical symptoms due to limited mobility from skeletal muscle disease 1.

Pulmonary Evaluation

Measure the following parameters:

  • Forced vital capacity (FVC)
  • Maximum inspiratory pressure (MIP)
  • Maximum expiratory pressure (MEP)
  • Peak cough flow (PCF)
  • Oxygen saturation (SpO2) in room air
  • End-tidal or blood CO2 if SpO2 ≤95% 2

Patients with FVC <50% predicted are at increased risk; those with FVC <30% are at high risk for respiratory complications 2.

Neuromuscular Blocker Management

Non-Depolarizing Agents

LGMD patients demonstrate increased sensitivity to rocuronium with prolonged onset and recovery times 6.

Reduce rocuronium dose by 50-75% from standard dosing 6. Use quantitative neuromuscular monitoring (train-of-four) to guide dosing and avoid overdosing 6.

Reversal Strategy

Sugammadex is the preferred reversal agent over neostigmine for steroidal muscle relaxants 6. Neostigmine carries risks of:

  • Interference with long-term myasthenia treatments
  • Secretion drying (with atropine)
  • Rhythm and conduction disorders
  • Slow, unpredictable response 6

Alternatively, consider benzylisoquinoline agents (atracurium/cisatracurium) which undergo organ-independent elimination and have more predictable pharmacokinetics 6.

Intraoperative Management

Machine Preparation

Prepare a trigger-free anesthesia workstation by:

  1. Removing all vaporizers
  2. Changing breathing circuit, reservoir bag, and CO2 absorbent
  3. Flushing with 100% oxygen at maximum flow for 90 seconds minimum
  4. Consider activated charcoal filters on inspiratory and expiratory limbs if immediate surgery required 7

Monitoring

  • Continuous SpO2 monitoring
  • End-tidal or blood CO2 monitoring whenever possible
  • Quantitative neuromuscular monitoring if muscle relaxants used
  • Standard ASA monitors 2, 3

Personnel and Setting

Perform procedures in optimal setting (operating room/PACU) with experienced anesthesiologist and respiratory therapist skilled in noninvasive positive pressure ventilation (NPPV) 2. Have ICU availability for postoperative management 2.

Respiratory Support Strategy

During Induction and Recovery

Patients with FVC <50% should receive assisted ventilation during induction and recovery; strongly consider for FVC <30% 2. Options include:

  • Manual ventilation with face mask
  • Mechanical ventilation via conventional or bilevel ventilators with face/nasal mask
  • Laryngeal mask airway
  • Endotracheal intubation with planned extubation to NPPV 2

Extubation Planning

For patients with FVC <50%, consider direct extubation to NPPV; strongly consider for FVC <30% 2. Use patient's home interface if already on NPPV to optimize comfort and success 2.

Delay extubation until:

  • Respiratory secretions well-controlled
  • SpO2 normal or at baseline in room air 2

Alternative: Regional Anesthesia

Neuraxial anesthesia (spinal/epidural) or peripheral nerve blocks are excellent alternatives when feasible 7, 4, 8. Regional techniques avoid:

  • Volatile anesthetic exposure
  • Need for neuromuscular blockade
  • Respiratory depression from general anesthesia

Recent case reports demonstrate successful spinal anesthesia for gynecological procedures in LGMD patients 4, 8.

Critical Pitfalls to Avoid

  1. Do not assume LGMD behaves like Duchenne muscular dystrophy - while similar precautions apply, LGMD has distinct genetic heterogeneity with variable cardiac and respiratory involvement 1

  2. Do not rely on clinical symptoms alone for cardiac assessment - patients may have significant cardiac dysfunction without symptoms due to limited mobility 1

  3. Do not use standard muscle relaxant dosing - sensitivity is significantly increased requiring dose reduction 6

  4. Do not discharge without adequate recovery - respiratory complications may manifest in recovery period, particularly in patients with FVC <50% 2

  5. Avoid propofol in egg/soya allergy with caution - while manufacturing likely removes allergenic proteins, a cautious approach is warranted 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.